Close Menu

collaboration

The firm will consolidate its businesses in newly-built headquarters in Fort Myers, Florida, which it plans to occupy around September.

By extending Terra to the Microsoft Azure cloud, the Broad and Verily Life Sciences hope to facilitate better data sharing, analysis, and reuse.

The firm has signed a three-year agreement with the University Hospital of Zurich to develop the test for use in kidney transplant recipients.

Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.

The drugmaker is supporting access to NGS testing in these countries to identify lung and pancreatic cancer patients with NRG1 fusions who can join its study.

Laboratories that purchase PGDx Elio genomic profiling tests will receive access to Qiagen's QCI Interpret One for rapid, evidence-based variant interpretation.

The partners will use PacBio's HiFi sequencing to develop assays for carrier screening, evaluating immune system responses, and diagnosing heritable diseases.

The companies say that the integration of the Nvidia DGX Station A100 will support "real-time analyses" of long-read DNA and RNA sequences.

The partners will use Adaptive's ImmunoSeq T-Map technology to analyze immune response to cancer antigens across AstraZeneca's oncology portfolio.

The firms will provide access to tumor profiling tests for both tissue and plasma samples, specifically PGDx's elio tissue complete and elio plasma resolve assays.

Pages

Imperial College London researchers are shifting away from testing a COVID-19 vaccine to focus on combating newly emerging SARS-CoV-2 variants, the Independent says.

According to the Associated Press, genetic genealogy has helped law enforcement officials identify an unknown victim of the Green River Killer.

In PNAS this week: target to reduce chemotherapy-induced cardiac injury, tool finds ancient endogenous RNA viruses, and more.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.